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Abstract
Background: SNAI1 can initiate epithelial-mesenchymal transition (EMT), leading to loss of epithelial characteristics
and, in cancer, to invasion and metastasis. We hypothesized that SNAI1 reactivation occurs in oral squamous cell
carcinoma (OSCC) where it might also be associated with focal adhesion kinase (FAK) expression and p63 loss.
Methods: Immunohistochemistry was performed on 46 tumors and 26 corresponding lymph node metastases. Full
tissue sections were examined to account for rare and focal expression. Clinical outcome data were collected and
analyzed.
Results: SNAI1-positivity (nuclear, ≥ 5% tumor cells) was observed in 10 tumors and 5 metastases (n = 12 patients).
Individual SNAI1(+) tumor cells were seen in primary tumors of 30 patients. High level SNAI1 expression (>10%
tumor cells) was rare, but significantly associated with poor outcome. Two cases displayed a sarcomatoid
component as part of the primary tumor with SNAI1(+)/FAK(+)/E-cadherin(-)/p63(-) phenotype, but disparate
phenotypes in corresponding metastases. All cases had variable SNAI1(+) stroma. A mesenchymal-like
immunoprofile in primary tumors characterized by E-cadherin loss (n = 29, 63%) or high cytoplasmic FAK
expression (n = 10, 22%) was associated with N(+) status and tumor recurrence/new primary, respectively.
Conclusions: SNAI1 is expressed, although at low levels, in a substantial proportion of OSCC. High levels of SNAI1
may herald a poor prognosis and circumscribed SNAI1 expression can indicate the presence of a sarcomatoid
component. Absence of p63 in this context does not exclude squamous tumor origin. Additional EMT inducers
may contribute to a mesenchymal-like phenotype and OSCC progression.
Background
Epithelial-mesenchymal transition (EMT) is a highly
conserved embryological process that permits epithelial
cells to dissolve their cell-cell connections and to remo-
del their polarity in order to acquire mesenchymal prop-
erties with migratory capability [1,2]. EMT can be
induced by a variety of molecules characterized by one
common activity which is the down-regulation of E-cad-
herin by transcriptional repression. The aberrant activa-
tion of this process has long been suspected to
contribute to tumor progression, i.e. invasion and
metastasis, which is responsible for the majority of
deaths related to malignant neoplasms [3]. Although
there is continued skepticism regarding the clinical rele-
vance of the phenomenon [4], evidence pointing
towards the contribution of EMT in human tumors has
been increasingly accumulated [5,6]. Sophisticated tech-
niques using in vitro systems and animal models have
allowed researchers to elucidate many of the molecular
mechanisms governing the phenotypic characteristics of
cells [7,8]. However, our knowledge regarding the speci-
fics of EMT in human neoplasms thus far remains pat-
chy at best, a situation owing partially to the complexity
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of human tissue, but also to the multitude of different
study designs and analytical tools.
A recent review by Becker et al. has summarized the
current state of knowledge with regard to the E-cad-
herin repressor SNAI1, the first EMT inducer originally
implicated with tumor progression [9]. SNAI1 (snail
h o m o l o g1 ;a l s oS n a i l ,S N A ,S N A H ,S L U G H 2 ,
dJ710H13.1) belongs to a family of zinc-finger transcrip-
tion factors which also comprises SNAI2 (Slug) and
SNAI3. The transcriptional repressor SNAI1 is an essen-
tial molecule which contributes to a series of coordi-
nated morphogenetic events that lead to mesoderm
formation in metazoans [10]. Its expression can be acti-
vated by different signaling cascades including receptor
tyrosine kinase (RTK) signaling which is commonly
deregulated in cancer [10]. In addition SNAI1 initiates a
transcriptional program that modulates other genes
involved in cell differentiation, leading to a general
downregulation of epithelial, and up-regulation of
mesenchymal, characteristics. Binding of SNAI1 to E-
box elements in the E-cadherin promoter region leads
to transcriptional repression of the CDH1 gene and
resulting loss of E-cadherin expression, which is consid-
ered a “hallmark” of EMT. Two other molecules pre-
viously linked to the loss of epithelial features and the
acquisition of a mesenchymal-like phenotype in cancer
cells are p63 and focal adhesion kinase (FAK). Downre-
gulation of ΔNp63a, the predominant p63 isoform in
squamous cell carcinoma, was recently shown to occur
in response to SNAI1 and to increase SCC invasiveness
[11-13]. No data examining this relationship in clinical
tissues have been presented thus far even though p63
expression is routinely considered evidence of squamous
differentiation in poorly differentiated carcinomas. FAK,
in contrast, has previously been linked to epithelial-
mesenchymal transition [14,15] and a migratory cellular
p h e n o t y p ei nm o r eg e n e r a lt e r m s[ 1 6 ] .T h ek i n a s ei sa n
essential part of a signaling complex formed by Src and
FAK which localizes to contact points between the cell
and the extra-cellular matrix, called focal adhesions.
Within these focal adhesions FAK contributes to a bi-
directional signaling by its ability to integrate stimuli
derived from the extracellular space via integrin recep-
tors and RTKs as well as the intracellular space due to
connections with the cytoskeleton. Signaling down-
stream of FAK involves a host of different molecules
and pathways. The more prominent downstream media-
tors are Rho-family GTPases which impact on the com-
position of the cytoskeleton as well as the MAPK and
the Akt/PKB pathway which regulate complex cellular
functions such as proliferation and survival [16].
I nt h i ss t u d yw ee x a m i n e dt h ee x p r e s s i o no fS N A I 1 ,
E-cadherin, FAK and p63 in a cohort of patients with
squamous cell carcinoma of the oral cavity (OSCC) trea-
ted at a center of tertiary/quaternary care. Taking into
account the focal nature of tumor-associated EMT we
used full sections of both primary tumors and metas-
tases to explore SNAI1-associated EMT by immunohis-
tochemistry. We also examined the specificity of
different commercially available SNAI1 antibodies,
including one antibody which, to the best of our knowl-
edge, has not been used previously for the study of
SNAI1 expression in formalin-fixed paraffin-embedded
(FFPE) clinical material.
Methods
Patients, Tissue Selection and Characteristics of Study
Cohort
This retrospective study was approved by the institu-
tional research ethics board of the University Health
Network, Toronto, ON (REB protocol #06-0805-T)
prior to initiation of any research activities. All require-
ments with regard to retrospective data collection as
well as retrieval and use of archived tissue specimens
were followed. Formalin-fixed paraffin-embedded (FFPE)
tissue of a longitudinal convenience cohort of OSCC
was retrieved from the UHN archive. 46/50 patients of
the initial cohort had sufficient FFPE tissue available to
be included in the study. All patients were diagnosed
and received treatment at our institution between the
years 1996 and 2000. For each patient one representa-
tive paraffin block from primary tumor and one lymph
node metastasis were selected after review of H&E
stained slides. Clinical information was accumulated
from electronic as well as paper files and data collected
by Cancer Care Ontario (Toronto, ON). 2/46 cases had
pre-operative radiation therapy. The metastasis of one
of these two cases was excluded from further analysis
d u et ol a c ko fv i a b l et u m o rt i ssue leaving 25/26 metas-
tases for immunohistochemical examination. One
patient had a reported one-time history of OSCC 25
years prior to inclusion in this study. In 37/46 patients a
current or former smoking history was reported. Other
characteristics of the cohort are summarized in Table 1.
Immunohistochemistry (IHC)
Several commercially available anti-SNAI1 antibodies
were evaluated for their applicability to paraffin-IHC (P-
IHC). Further specificity testing then focused on
SC10432 (goat polyclonal, [E-18]; St. Cruz Biotechnol-
ogy, Santa Cruz, CA) and AF3639 (goat polyclonal;
R & DS y s t e m s ,M i n n e a p o l i s ,M N ) .X e n o g r a f t so ft w o
previously studied cell lines SiHa and ME180 obtained
from the American Type Culture Collection (ATCC,
Manassas, VA) were employed as controls for all stain-
ing procedures [17]. Although AE1/AE3-positive, both
cell lines represent opposite ends of the epithelial-
mesenchymal spectrum with an E-cadherin(-), p63(-),
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(+), p63(+), SNAI1(-), FAK(+/-) phenotype in ME180
(Additional File 1: A). In addition, three different FFPE
tissue samples were used for initial antibody testing: (i)
1
st trimester human placenta, (ii) SiHa xenograft tissue
derived from SCID mice after s.c. suspension injection
and (iii) tissue from a spindle cell carcinoma specimen
of the piriform sinus with vimentin positivity and foci of
osteosarcoma. To validate the nuclear SNAI1 staining
seen with those tissues two tests were performed. First,
SC10432 was tested in all specimens after prior incuba-
tion with the corresponding blocking peptide SC10432P
at 1:10 protein ratio versus PBS (Additional File 1: B).
Second, immunoblotting was performed on SiHa cell
lysates treated with SNAI1 siRNA versus control. Immu-
noblots revealed a singular band at ~30 kDa with a
clear decrease after treatment (Additional File 1: C). By
IHC, an essentially identical nuclear reactivity was found
for both SC10432 and AF3639. However, AF3639 in our
hands produced less cytoplasmic staining and a stronger
nuclear signal than SC10432 (Additional File 1: D).
Clinical FFPE material was cut at 4 μm thickness and
processed with standard procedures. Microwave antigen
retrieval was performed in1 0m MC i t r a t eb u f f e r ,p H
6.0, for 10 min. The following antibodies and conditions
were applied: SC10432 (1:200, overnight) and AF3639
(1:1000, overnight), rabbit polyclonal FAK (#3285, 1:200,
overnight; Cell Signaling Technology, Danvers, MA),
mouse monoclonal HMWK 34bE12 (M0630, 1:100, 1
hr; Dako, Mississauga, ON), mouse monoclonal Vimen-
tin (Vim3B4, 1:200, 1 hr; American Research Products,
Belmont, MA), mouse monoclonal E-cadherin (36B5,
1:100, overnight; Vector Labs, Burlington, ON), mouse
monoclonal p63(7JUL, 1:50, 2 hrs; Vector Labs) and
human cytokeratin cocktail (AE1/AE3, 1:200, 1 hr;
Dako). Secondary antibodies were biotin-labeled IgG
(Vector Labs). Linking reagents were Streptavidin-HRP
(ID Labs, London, ON) and/or Streptavidin-AP (Dako).
Labeling reagents were NovaRed (SK-4800, Vector
Labs), DAB+AP double-labeling: DAB (K3466, Dako) &
AP VectorRed (SK-5100, Vector Labs). Sections were
counterstained with Gill modified hematoxylin and cov-
erslipped with Permount* Mounting Medium (Fisher
Scientific, Nepean, ON). First-trimester placenta and
xenograft tissue were carried with every staining series
as controls.
Cell Culture, Transfection and Immunoblotting
SiHa and ME180 cells were cultured under recom-
mended conditions. Xenografts were grown subcuta-
neously in SCID mice after suspension injection.
Experimentation involving animals was done under pro-
tocols approved according to the regulations of the
Canadian Council on Animal Care. Transfection of SiHa
cells with On-Targetplus SMARTpool human-SNAI1
siRNA (Dharmacon, Lafayette, CO) and On-Targetplus
siControl non-targeting siRNA was done using Oligofec-
tamine™ reagent (Invitrogen, Burlington, ON) according
to protocols supplied by the manufacturer. Western
immunoblotting with anti-SNAI1 (AF3639, 1:1000, over-
night, 4°C) was done as previously described [18].
Scoring and Statistical Methods
IHC scoring was done by a pathologist-in-training (JS)
and a board-certified pathologist (WRG). Scoring was
performed on full sections to account for rare and
Table 1 Characteristics of the Study Cohort
Parameter Measurement Number of Cases (%)
Patients Count 46 (100%)
Age Mean 60.2
Median 63
Range 34-82
Sex Male 30
Female 16
Follow Up (months) Mean 44.4
Median 21.5
Range 2-141
Time to Event
(months)
Mean 13
Median 9
Range 2-51
TNM T1 6 (13%)
T2 18 (39%)
T3 9 (20%)
T4 13 (28%)
N0 20 (44%)
N1 7 (15%)
N2 19 (41%)
N2a 2 (4%)
N2b 14 (30%)
N2c 3 (7%)
M0 46 (100%)
Grade G1 4 (9%)
G2 37 (80%)
G3 5 (11%)
Location Tongue 27 (59%)
Floor 5 (11%)
Tongue+Floor 8 (17%)
Right retromolar
trigone
2 (4%)
Left retromolar
trigone
1 (2%)
Right buccal 2 (4%)
Left inferior alveolar 1 (2%)
Adverse Event* Yes 25 (54%) [2
nd primary:
4/25]
No 21 (46%)
*Adverse Event: Tumor recurrence or second primary OSCC
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front. A histology scoring system (H-score) was used to
account for area and staining intensity since consider-
able heterogeneity was observed in individual sections:
E-cadherin, FAK, p63:
Intensity Category 0
Intensity Category 1 × Area of Category 1 (%) +
Intensity Category 2 × Area of Category 2 (%) +
Intensity Category 3 × Area of Category 3 (%) = H-
Score
FAK scoring was done for the predominant cytoplas-
mic compartment; however occasional nuclear staining
was also seen. E-cadherin was scored with intensity 2
and 3 for weak and strong membrane staining, respec-
tively. Cytoplasmic staining of any intensity without
membrane labeling was considered intensity 1 [17]. P63
was scored for nuclear staining only, and no significant
labeling of any other cell compartments was seen.
SNAI1 staining was categorized as follows:
SNAI1:
Category 0: no tumor cells with nuclear staining
Category 1: rare tumor cells with nuclear staining,
less than 5%
Category 2: ≥ 5% tumor cells with nuclear staining
(= SNAI1-positive)
SNAI1 in tumor-surrounding stroma was assessed
using the following categories: absent (no SNAI1 even
at 400×), rare/occasional cells (single cells can be found
at 400×), frequent (SNAI1 positive stroma cells are read-
ily detectable), abundant (positivity of a majority of
stroma cells easily discernable at 100×).
Statistical analysis of categorical data was performed
using Fisher’s exact test. Spearman nonparametric corre-
lation was used to assess the relationship between vari-
ables. Kaplan-Meier survival data were compared using
the log-rank test. Two-tailed p values < 0.05 were con-
sidered statistically significant. Statistical software was
GraphPad Prism, Version 5.01 (GraphPad Software, La
Jolla, CA).
Results
SNAI1 Expression in Tumor Cells and Tumor-Associated
Stroma of OSCC
Immunohistochemistry (IHC) for SNAI1 in clinical
material was performed in two parallel series using both
antibodies, SC10432 and AF3639. In specimens display-
ing SNAI1 nuclear positivity the same cell population
was labeled by both antibodies. However, AF3639 pro-
duced strong nuclear staining with better signal-back-
ground-ratio. Thus, final scoring and assessment was
performed based on AF3639 stained slides. SNAI1
expression in our series of OSCC was found to occur as
an infrequent event that was mostly observed in few,
scattered tumor cells representing less than 5% of the
entire tumor population. These rare SNAI1(+) cells
were frequently seen either in the vicinity of inflamma-
tion or close to the invasion front of the tumor. How-
ever, at this level SNAI1 expression was observed in the
majority (30/46; 65%) cases. 10 (22%) cases displayed
SNAI1 expression at a level of ≥ 5% (Category 2:
SNAI1-positive) and 5 of these cases displayed ≥ 10%
SNAI1 positivity in the primary tumor. 6 cases (13%)
were entirely negative for SNAI1 in tumor cells. If
lymph node metastases were considered in addition to
the primary tumors, 2 more cases were determined to
be SNAI1-positive resulting in a total of 12/46 (26%)
cases. Overall 5/25 (20%) lymph node metastases were
SNAI1-positive, 20/25 (80%) had less than 5% SNAI1
expression and none of the metastases was entirely
negative for SNAI1. Of the SNAI1-positive metastases
3/5 were associated with SNAI1 expression in primary
tumors and 2/5 cases were found SNAI1-positive in the
metastasis only. Of the 10 cases categorized as SNAI1-
positive based on the primary tumor, 6 had lymph node
metastases at surgery. 5/6 of these lymph nodes were
examined by IHC after exclusion of one tissue sample
that lacked viable tumor. 3 of the remaining 5 metas-
tases were categorized as SNAI1-positive, 2/5 contained
rare (<5%) tumor cells expressing SNAI1. Two represen-
tative examples of SNAI1 expression in tumor cells are
shown in Figure 1A and 1B.
SNAI1 nuclear staining was more frequent in stroma
than in tumor cells. 6 (13%) cases were categorized as
“abundant”, 25 (54%) as “frequent” and 15 (33%) as
“rare/occasional” for stromal SNAI1expression. All 6
cases of the stromal category “SNAI1-abundant” had
SNAI1 expression at a <5% level in the corresponding
tumor area. Of the 25 cases classified as “SNAI1-fre-
quent” based on their stroma, 4/25 corresponding
tumors were negative, 18/25 had SNAI1 expression in
<5% tumors cells and 3/25 were categorized as SNAI1-
positive (≥ 5%). Finally, in the group of cases with “rare/
occasional” SNAI1 expression in tumor stroma, 2/15
corresponding tumors were negative, 6/15 had SNAI1
expression in <5% tumors cells and 7/15 were categor-
ized as SNAI1-positive (≥ 5%). Chromatic double-stain-
ing for HMWK or Vimentin together with SNAI1 in
several cases with prominent stromal expression indi-
cated a mutually exclusive labeling between SNAI1 and
HMWK, but coincidence of SNAI1 with Vimentin (Fig-
ure 1C and 1D). Among normal tissue constituents
nuclear SNAI1 expression was most frequently seen in
endothelial cells (Figure 1E), and there was an impres-
sion of a more frequent SNAI1 positivity in vascular
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Page 4 of 12Figure 1 SNAI1 expression occurs in tumor cells, tumor-associated stroma and endothelium. A, SNAI1 expression (arrow) in an OSCC with
5% positivity in the tumor cells of the primary site. B, SNAI1 expression (arrows) in an OSCC with 20% positivity in the tumor cells of the primary
site. C, Vimentin (cytoplasmic, red) and SNAI1 (nuclear, brown) show co-expression in stromal cells with fibroblastic morphology. D, HMWK
(cytoplasmic, red) in strands of diffusely infiltrating OSCC and SNAI1 are mutually exclusive. E, SNAI1 in endothelium in the vicinity of the same
OSCC shown in C and D.
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sion of SNAI1 was not included into the assessment of
the stroma.
Relationship between SNAI1 Expression and Clinical
Parameters
To examine the clinical impact of SNAI1 expression, the
distribution of cases with Category 2 labeling and higher
(≥ 5% or ≥ 10% SNAI1-positive) among different clini-
copathological parameters was examined. No statistically
significant relationships were found with patient gender,
TNM stage, nodal status, grade, perineural and lympho-
vascular invasion as well as adverse events defined as
recurrence or second prima r yO S C C .N e x t ,w es t u d i e d
SNAI1 expression in tumor cells with regard to patient
prognosis. No significant difference with regard to
event-free survival (EFS; p = 0.3090) and disease-specific
survival (DSS; p = 0.1613) was found for the cut-off
used to define SNAI1-positive staining (Category 2: ≥
5% tumor cells). However, a small group of cases with
SNAI1-positivity in more than 10% tumor cells (n = 4/
46) was characterized by both significantly shorter EFS
and DSS (p = 0.0259 and p = 0.0341, respectively).
Inclusion of 2 additional cases displaying SNAI1-positiv-
ity >10% in lymph node metastases defined a poor-prog-
nosis group with significantly shorter EFS (median 5 vs.
42 months, p = 0.0007) and DSS (median 9 vs.u n d e -
fined, p = 0.0005) (Figure 2 and Additional File 2).
Next, SNAI1 expression in tumor-associated stroma was
examined with regard to outcome parameters. For the
three different categories with “abundant”, “frequent”
and “rare/occasional” SNAI1 expression, 4/6 (67%), 14/
25 (56%) and 7/15 (47%) adverse events as well as 4/6
(67%), 10/25 (40%) and 7/15 (47%) disease-specific
deaths were present, respectively. Analysis of EFS and
DSS did not reveal significant differences between these
groups.
Gain of FAK, Loss of E-cadherin and p63 Are Early
Alterations in OSCC
Cytoplasmic FAK expression (FAKc) in cancer and
metastases was mostly weak to moderate, and consider-
able intra-tumoral heterogeneity was observed. A similar
situation was found for E-cadherin with areas of distinct
membrane staining and areas of E-cadherin loss occa-
sionally present in the same tumor. Overall, an inverse
relationship was noted between FAK and E-cadherin
expression (Additional File 3: A). This inverse relation-
ship was statistically significant if all tissues including
tumor-adjacent normal mucosa, primary tumors and
metastases were considered (Spearman r:-0.6472, p <
0.0001), but not if the relationship was assessed for pri-
mary tumors alone (Spearman r: -0.1864, p = 0.2149).
Comparing the H-scores for FAK and E-cadherin
between the three different tissue compartments, a sig-
nificant difference was noted for mucosa versus tumor
or metastasis (Additional File 3: B+C). However, no sig-
nificant difference was found between tumor and metas-
tasis indicating that FAK gain and E-cadherin loss might
be early events during tumor development. P63 was
examined in the same manner and a more subtle, but
significant loss of expression was found comparing the
basal/parabasal compartment of normal mucosa with
tumor or metastasis. Again there was no significant dif-
ference between tumor and metastases (Additional File
3: D).
Comparison between cases with strong cytoplasmic
FAK staining (score ≥ 2 in >10% tumor area: FAKc
high) and weak cytoplasmic FAK staining (score ≤ 1i n
≥ 90% tumor area: FAKc low) revealed a significantly
Figure 2 High level SNAI1 expression, although infrequent, is associated with poorer outcome in OSCC. A, Disease-specific survival and
B, Event-free survival are significantly shorter (p = 0.0341 and p = 0.0259, respectively) in a small group of patients (n = 4) with high SNAI1
expression in tumor cells (>10%).
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36, 44%; p = 0.0105, Figure 3A), shorter event-free sur-
vival (EFS; FAKc h i g h :m e d i a n9m o n t h s ,n=1 0vs.
FAKc low: median: undefined, n = 36; p = 0.0021) and a
trend towards shorter overall survival (OS; FAKc high:
median 11 months vs.F A K c low: median: 68 months; p
= 0.0535) in the former group, indicating a link between
the kinase and tumor progression. Furthermore, E-cad-
herin loss (Score ≤ 2i n≥ 90% tumor area) was asso-
ciated with a significantly higher proportion of positive
nodal status at surgery (21/29, 72% vs. 5/17, 29%; p =
0.0064, Figure 3B). E-cadherin loss was not associated
with shorter EFS and OS in our cohort. About twice the
number of patients that suffered an adverse event had a
history of positive nodal status at surgery (16/25, 64%)
compared to only 9/25 (36%) patients who developed an
event without prior lymph node metastasis. However,
this relationship was not statistically significant (p =
0.3721).
Two Cases with Sarcomatoid Component Suggest EMT in
OSCC
Closer examination of the SNAI1(+) group of cases
revealed 2 patients with distinct SNAI1-expressing
tumor areas of 80% and 30% associated with p63 loss
(Additional File 3: E). The first case was a 78 year old
female patient with a T3N1M0 SCC of the tongue initi-
ally graded as G2-3. This patient suffered a local recur-
rence 2 months after surgery despite negative margins
and lack of perineural as well as lymphatic/vascular
invasion and died after a total follow-up of 4 months.
The primary tumor in this case presented as exophytic
mass with a minor component of distinctly squamous
cell nests and a major, poorly differentiated component
with E-cadherin(-), p63(-), SNAI1(+), FAK(+) phenotype
(Figure 4 and Additional File 4). The nests of the squa-
mous component displayed focal continuity from adja-
cent dysplastic epithelium and were found embedded
into the sarcomatoid component throughout the tumor
mass. Double labeling for SNAI1 with HMWK and
SNAI1 with Vimentin confirmed the EMT phenotype of
the sarcomatoid component with mutually exclusive
staining for SNAI1 and HMWK. Weak AE1/AE3 stain-
ing was retained in most of the sarcomatoid component,
compared to strong positivity in squamous nests. The
lymph node metastasis in this case displayed an E-cad-
herin(+) phenotype in the majority of cells with focal
low level SNAI1 expression and lack of E-cadherin
membrane staining.
The second case was a 63 year old female with a
T 2 N 2 c M 0p o o r l yd i f f e r e n t i a t e dS C Co ft h et o n g u e .
Lymphatic/vascular, but no perineural invasion was
reported. 26 months after surgery of the primary tumor
this patient developed a right temporal fossa mass
lesion. Resected tissue from this lesion confirmed distant
recurrence of the SCC. Subsequently a right upper lobe
lung mass was detected as well. The patient was referred
for palliative care and died after a total follow-up of 28
months. Slide review revealed a distinct, well circum-
scribed area within the primary tumor displaying E-cad-
herin(-), p63(-), SNAI1(+), FAK(+) phenotype (Figure 5
and Additional File 5). The lymph node metastasis in
this case was strikingly p63 negative, but displayed
SNAI1 expression in only 10% of all tumor cells. E-cad-
herin was cytoplasmic with almost complete absence of
membrane staining. AE1/AE3 produced weak to moder-
ate staining and Vimentin was positive in ~90% cells in
the sarcomatoid component of the primary tumor. The
metastasis from the right temporal fossa was character-
ized by a strong E-cadherin membrane staining and
strong AE1/AE3 reactivity in the bulk of the tissue.
However, significant nuclear SNAI1 expression was pre-
sent, focal areas of E-cadherin loss could be discerned
and p63 was absent.
Figure 3 FAK expression and E-cadherin loss are associated
with adverse events and lymph node metastasis, respectively.
A, FAKc high (score ≥ 2 in >10% tumor area) cases have a
significantly higher proportion of adverse events (tumor recurrence/
2
nd primary tumor: 9/10) than FAKc low cases (16/36, p = 0.0105). B,
Membranous E-cadherin(+) cases (score 3 in >10% tumor area) have
a significantly lower proportion of lymph node metastases (5/17)
than E-cadherin(-) cases (21/29, p = 0.0064).
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We show here that SNAI1-associated EMT is present in
OSCC and potentially contributes to tumor progression
in at least a subset of tumors. The latter is exemplified
by two cases displaying a sarcomatoid tumor component
with high level SNAI1 expression. However, SNAI1
expression in tumor cells was an infrequent event in the
majority of cases (usually <<5%) and more commonly
noted in scattered individual cells or small groups, parti-
cularly at the invasion front and in the vicinity of
inflammation. Although the presence of a SNAI1-posi-
tive tumor component of >10% area was associated with
a poorer prognosis in our cohort, the significance of
occasional SNAI1-positive cells for patient outcome
remains unclear. SNAI1 expression in the tumor stroma
was a frequent observation, raising further questions
regarding the origin of these cells [19] and the contribu-
tion of the stromal compartment to the malignant phe-
notype [20,21].
Considering the focal nature of EMT we decided to
examine complete tissue sections of primary tumors and
metastases. With regard to the staining pattern and fre-
quency of SNAI1 expression our results are comparable
to other studies previously performed with non-com-
mercial antibodies [22-25].T w or e c e n ts t u d i e sw h i c h
examined SNAI1 in HNSCC by IHC were not able to
detect substantial expression of the protein in the
epithelial tumor component [26,27]. Interestingly, the
study by Zidar et al.i n c l u d e dag r o u po fs p i n d l ec e l l
carcinomas which showed SNAI1-positivity in 19/30
cases [26]. In our randomly collected cohort we identi-
fied two cases with sarcomatoid component which,
although not distinctly of spindle cell type, showed a
clearly circumscribed area of SNAI1-positivity with
characteristics of a mesenchymal phenotype. It is tempt-
ing to speculate that the lymph node metastasis of case
1 and the intracranial metastasis of case 2 show E-cad-
herin expression due to the reverse process of EMT:
mesenchymal-epithelial transition (MET; also epithelial-
mesenchymal reverting transition, EMrT). Current
research increasingly focuses on both shifts in tumor
cell phenotype since re-establishment of cell-cell
Figure 4 Immunohistochemical profile of OSCC with sarcomatoid component, Case 1. A,S N A I 1 ;B, E-cadherin; C,F A Ka n dD,p 6 3a r e
differentially expressed in sarcomatoid (A+C) and squamous (B+D) component. Magnified inserts correspond to framed areas in the section
overview. An asterisk in insert C indicates strands of squamous cell carcinoma intermingled with the sarcomatoid component. Dual staining of
SNAI1 (nuclear, brown) and E, HMWK or F, Vimentin (red) illustrates the mesenchymal character of the sarcomatoid tumor component. G, Lymph
node metastasis with focal E-cadherin loss (arrow).
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of the metastatic target organ [28]. Also, it is becoming
increasingly accepted that tumor cells may not necessa-
rily undergo a complete transition, but rather seem to
adopt different “quasi-mesenchymal” states which, in
addition to the transient nature of EMT and the contri-
bution of other E-cadherin repressors, may explain the
lack of correlation between SNAI1 expression and the
mesenchymal phenotype, including E-cadherin loss.
As in several previous studies (Additional file 6),
S N A I 1e x p r e s s i o ni no u rc o h o rt was not significantly
associated with E-cadherin loss. This observation
appears consistent with the proposed focal and/or tran-
sient nature of tumor-associated EMT as well as the
contribution of additional EMT mediators. Similarly,
high cytoplasmic FAK expression was not exclusively
found in SNAI1-positive tumors pointing towards other
mechanisms which may confer a migratory phenotype.
Also consistent with earlier studies, E-cadherin and FAK
were most noticeably altered between normal mucosa
and tumor [29-32], although a range of different expres-
sion levels and considerable intra-tumoral heterogeneity
was seen. A marker whose absence might indicate EMT
in cancers arising from squamous epithelia is p63.
Although overall less intensely labeled than in basal and
parabasal cells of normal mucosa, p63 was generally pre-
served in OSCC. However, in two poorly differentiated
OSCC a complete absence of p63 expression in the sar-
comatoid component was found indicating a more com-
plete transition towards the mesenchymal phenotype.
Interest in the role of EMT and its reverse process,
MET, in tumor progression has increased exponentially
in the last few years [33], although the clinical signifi-
cance of the phenomenon has been a matter of continu-
ing debate [4]. One obstacle has been the fact that in
vivo proof of the phenomenon has been difficult to
obtain. The reasons for this may be manifold, one possi-
bly being the focal and transient nature of the process,
which may employ a number of different mediators
besides SNAI1 [34]. Since the initial description of the
Figure 5 Immunohistochemical profile of OSCC with sarcomatoid component, Case 2. A, Membranous E-cadherin expression is preserved
in the squamous component (1), but lost in the sarcomatoid component (2, arrow). Small images: high power views of the framed areas in the
section overview. Corresponding FAK staining (arrow ® right) shows accentuation of the invasion front in the squamous component (1), but
strong cytoplasmic staining throughout the tumor in the sarcomatoid component (2). Size bars: 0.2 mm. B, P63 staining is strong in adjacent
mucosa (1) and the squamous tumor component (2), but absent in the sarcomatoid component (3). A magnified area from region 3 shows
nuclear SNAI1 positivity (arrow ® right). A lymph node metastasis resected at initial presentation is completely negative for p63 (see overview
and magnified insert; asterisk indicating the carcinoma). C, A temporal fossa metastasis 26 months after initial presentation is positive for E-
cadherin and SNAI1, but negative for p63.
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more aggressive tumor phenotype [35], several studies
have examined the potential consequences of EMT in
SCC of the head and neck (HNSCC) in vitro [36-38]
and in vivo [25,26,32,39,40] using a range of different
methods. Some of the confusion over the prevalence of
SNAI1 expression in human cancers may also be
derived from the use of different antibodies and IHC
scoring methods leading to obvious differences particu-
larly with regard to the subcellular compartment consid-
ered positive for SNAI1 staining (Additional file 6).
Thus, we carefully examined the specificity of the
SNAI1 antibodies used in our study employing different
controls and analytical methods.
Conclusions
Reactivation of components of the developmental EMT
program likely contributes to tumor progression in at
least a subset of OSCC. Although SNAI1 expression is an
infrequent event, its presence in a significant proportion
of tumor cells may be associated with a poor prognosis
and can herald the presence of a sarcomatoid compo-
nent. P63 may be negative in this situation which can
complicate histopathologic diagnosis in cases with occult
primary tumor. Further investigation of other E-cadherin
repressors (e.g. ZEB1) including a larger cohort will help
to elucidate the contribution of EMT to tumor progres-
sion in OSCC and other cancers.
Additional file 1: Controls and antibody specificity. A, SiHa and
ME180 xenografts grown in SCID mice show mesenchymal and
squamous characteristics, respectively. Sections of both xenografts were
used as positive and negative controls. B, Placenta, SiHa xenograft and
spindle cell carcinoma (SpCC) of the head and neck were used to test
SNAI1 antibody specificity in a competition assay. Absence of staining
after incubation with SC10432P blocking peptide confirms specific
staining in cell nuclei. C, SiRNA treatment of SiHa cells confirms antibody
specificity in an immunoblot performed with AF3639 on SiHa monolayer
lysates. D, Comparison of AF3639 and SC10432 shows identical nuclear
staining of the extravillous trophoblast. IHC with SC10432 additionally
results in some focal cytoplasmic staining (asterisk) which can also be
seen inside the villi in section B of this figure.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6890-10-1-
S1.TIFF]
Additional file 2: High level SNAI1 expression is associated with
poor outcome. A, DSS and C, EFS are not significantly shortened by low
level SNAI1 (≥ 5%) expression in our cohort. However, SNAI1-positivity in
>10% cells of primary tumor and/or metastasis is associated with
significantly shorter B, DSS and D, EFS by univariate analysis (log rank
test).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6890-10-1-
S2.TIFF]
Additional file 3: FAK, E-cadherin and p63 expression are
specifically altered in tumors and metastases. A, A significant inverse
relationship was found between E-cadherin and FAKc expression.
Spearman’s rank correlation and 95% confidence interval are shown. The
relationship was not significant for tumors only. B, FAKc; C, E-cadherin
and D, p63 are significantly different in tumors and metastases
compared to mucosa adjacent to tumor. An arrow in D indicates the
p63-negative metastasis of case 2. E, p63 is not significantly altered with
respect to SNAI1 expression levels in the majority of OSCC. However, two
cases with sarcomatoid component show p63 loss and SNAI1-positivity.
(Open and black symbols in diagrams B-E correspond to case 1 and 2,
respectively).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6890-10-1-
S3.TIFF]
Additional file 4: OSCC with sarcomatoid component, Case 1. A,
Slide overview and magnified insert illustrate the morphology of the
primary tumor in case #1 (haematoxylin & eosin). B, Staining with AE1/
AE3 cytokeratin cocktail results in strong labeling of the squamous
component (arrow), weak-absent labeling of the sarcomatoid component
(arrowheads) and absence of labeling in the stroma (asterisk).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6890-10-1-
S4.TIFF]
Additional file 5: OSCC with sarcomatoid component, Case 2. A,
Slide overview and magnified insert illustrates the morphology of the
primary tumor in case #2 (haematoxylin & eosin). Arrowhead in insert
indicates the sarcomatoid, arrow the squamous component. B, Staining
with AE1/AE3 cytokeratin cocktail results in strong-moderate labeling of
the squamous component (arrow), moderate labeling of the sarcomatoid
component (arrowhead) and absence of labeling in the stroma (asterisk).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6890-10-1-
S5.TIFF]
Additional file 6: Supplemental table. Studies on SNAI1 performed
with immunohistochemistry on FFPE tissue specimens.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6890-10-1-
S6.DOC]
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